Posters MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity MaaT Pharmaavril 28, 2025
Posters MaaT033 pour assurer un microbiote intestinal optimal afin d’améliorer la survie des patients recevant une allo-CSH : Essai PHOEBUS MaaT Pharmadécembre 2, 2024
Posters PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeneic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only) MaaT Pharmadécembre 2, 2024
Posters Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors MaaT Pharmanovembre 29, 2024
Posters Baseline and Safety data from IASO, a pioneering open-label phase 1b trial assessing the safety, tolerability and gut microbiota analysis of an oral microbiotherapy in amyotrophic lateral sclerosis Dispose d’un menu contextuel Dispose d’un menu contextuel MaaT Pharmanovembre 18, 2024
Posters Pooling of faecal material results in standardized and high taxonomic and functional richness microbiotherapy products MaaT Pharmajuillet 22, 2024
Posters Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial MaaT Pharmajuin 7, 2024
Posters A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial MaaT Pharmamars 25, 2024
Posters Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors MaaT Pharmamars 19, 2024
Posters Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe MaaT Pharmadécembre 11, 2023
